Holen Sie sich die Stockscreener-App
21.69
2.26%
0.48
Handel nachbörslich:
21.69
Schlusskurs vom Vortag:
$21.21
Offen:
$21.16
24-Stunden-Volumen:
60,911
Relative Volume:
0.59
Marktkapitalisierung:
$505.53M
Einnahmen:
$36,000
Nettoeinkommen (Verlust:
$-274.45M
KGV:
-1.8365
EPS:
-11.8105
Netto-Cashflow:
$-150.80M
1W Leistung:
+12.44%
1M Leistung:
-3.43%
6M Leistung:
+21.51%
1J Leistung:
+133.33%
1-Tages-Spanne:
$21.16
$22.66
1-Wochen-Bereich:
$19.53
$22.66
52-Wochen-Spanne:
$7.65
$45.00
Lyell Immunopharma Inc Stock (LYEL) Company Profile
Firmenname
Lyell Immunopharma Inc
Sektor
Branche
Telefon
650 695-0677
Adresse
201 HASKINS WAY, SOUTH SAN FRANCISCO
Compare LYEL vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LYEL
Lyell Immunopharma Inc
|
21.69 | 494.34M | 36,000 | -274.45M | -150.80M | -11.81 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Lyell Immunopharma Inc Stock (LYEL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-03-09 | Eingeleitet | Citizens | Mkt Outperform |
| 2025-12-09 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2024-10-30 | Herabstufung | BofA Securities | Buy → Underperform |
| 2024-06-27 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-28 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2022-11-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2022-11-11 | Herabstufung | Goldman | Buy → Neutral |
| 2022-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-07-12 | Eingeleitet | BofA Securities | Buy |
| 2021-07-12 | Eingeleitet | Goldman | Buy |
| 2021-07-12 | Eingeleitet | JP Morgan | Overweight |
| 2021-07-12 | Eingeleitet | Morgan Stanley | Overweight |
Alle ansehen
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX) - Defense World
Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2%Time to Buy? - MarketBeat
US Stocks Recap: How sensitive is Lyell Immunopharma Inc to inflation2026 Risk Factors & Reliable Entry Point Alerts - baoquankhu1.vn
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
LYEL Technical Analysis & Stock Price Forecast - Intellectia AI
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - ca.investing.com
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and Statistics - indexbox.io
Lyell Immunopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Misses Expectations By $5.53 EPS - MarketBeat
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma misses Q4 revenue estimates - TradingView
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy - Stock Titan
ARCH Venture Fund XIII boosts Lyell (LYEL) stake with 488K-share purchase - Stock Titan
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma, Inc. announced that it has received $99.999968 million in funding - marketscreener.com
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell names Smital Shah as Chief Financial and Business Officer - TradingView
Lyell Immunopharma (NASDAQ: LYEL) hires Smital Shah as finance chief - Stock Titan
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Lyell Immunopharma Announces Closing of Additional $50 - GlobeNewswire
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com Australia
Citizens Initiates Coverage of Lyell Immunopharma (LYEL) with Market Outperform Recommendation - MSN
HC Wainwright & Co. Maintains Lyell Immunopharma (LYEL) Neutral Recommendation - MSN
Take Profit: Will Lyell Immunopharma Inc benefit from rate cutsTrade Volume Summary & Accurate Intraday Trading Signals - baoquankhu1.vn
Fund Flows: Is Lyell Immunopharma Inc impacted by rising ratesIndex Update & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Breakouts Watch: Is Lyell Immunopharma Inc stock trending bullishJuly 2025 Weekly Recap & Long-Term Capital Growth Ideas - baoquankhu1.vn
Lyell Immunopharma Inc expected to post a loss of $2.37 a shareEarnings Preview - TradingView
LYEL SEC FilingsLyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Lyell Immunopharma (LYEL) to Release Earnings on Tuesday - marketbeat.com
Lyell Immunopharma Advances GCC19CART Trial in Metastatic Colorectal Cancer: What Investors Should Know - TipRanks
LYEL.O Technical Analysis & Stock Price Forecast - Intellectia AI
LYEL Technical Analysis & ETF Price Forecast - Intellectia AI
Lyell Immunopharma Announces Participation in March Investor Conferences - GlobeNewswire
Cancer therapy developer Lyell to join three investor conferences in March - Stock Titan
What is the long term forecast for Lyell Immunopharma Inc. stockEarnings Recap Report & Risk Managed Investment Strategies - mfd.ru
Finanzdaten der Lyell Immunopharma Inc-Aktie (LYEL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Lyell Immunopharma Inc-Aktie (LYEL) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| ARCH Venture Fund XIII, L.P. | 10% Owner |
Mar 06 '26 |
Buy |
25.61 |
488,090 |
12,499,985 |
1,426,528 |
| Seely Lynn | President and CEO |
Feb 11 '26 |
Sale |
23.39 |
7,455 |
174,372 |
74,266 |
| Hill Stephen J. | Chief Operating Officer |
Feb 11 '26 |
Sale |
23.39 |
1,236 |
28,910 |
17,795 |
| Lee Gary K. | Chief Scientific Officer |
Feb 11 '26 |
Sale |
23.39 |
1,671 |
39,085 |
16,938 |
| Hill Stephen J. | Chief Operating Officer |
Feb 10 '26 |
Sale |
23.12 |
109 |
2,520 |
19,031 |
| Lee Gary K. | Chief Scientific Officer |
Feb 10 '26 |
Sale |
23.12 |
147 |
3,399 |
18,609 |
| Seely Lynn | President and CEO |
Feb 10 '26 |
Sale |
23.12 |
438 |
10,127 |
81,721 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Feb 10 '26 |
Sale |
23.12 |
254 |
5,872 |
15,637 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Dec 24 '25 |
Sale |
38.67 |
1,136 |
43,929 |
8,077 |
| Bulis Veronica Sanchez | VP, Corporate Controller |
Dec 30 '25 |
Sale |
32.32 |
936 |
30,252 |
7,141 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):